MDP:CA Stock

Research Capital analyst Andre Uddin maintained his “Buy” rating and C$5.55 target on Medexus Ph... Read More

Leede Financial analyst Douglas Loe said Aug. 13 that Medexus Pharmaceuticals’ (Medexus Pharmaceut... Read More

Research Capital analyst Andre Uddin maintained a “Buy” rating and C$5.55 price target on Medexu... Read More

Following a key product update, Raymond James analyst Michael W. Freeman remains bullish on Medexus ... Read More

An FDA approval could send one Canadian-listed stock flying, says Raymond James analysts Michael W. ... Read More